P. Qiu

发表

A Cluster of Metabolic-Related Genes Serve as Potential Prognostic Biomarkers for Renal Cell Carcinoma

Chunlan Hong, Changyu Li, Junhao Huang, 2022, Frontiers in Genetics.

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.

A. Tafreshi, J. Carles, S. Oudard, 2022, European urology.

Chang qing formula ameliorates colitis-associated colorectal cancer via suppressing IL-17/NF-κB/STAT3 pathway in mice as revealed by network pharmacology study

Yiheng Wang, Changyu Li, Jingqun Liu, 2022, Frontiers in Pharmacology.

625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update

L. Appleman, G. Gravis, E. Yu, 2020 .

Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test

M. Marton, R. Cristescu, A. Albright, 2022, BMC cancer.

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

P. Ott, Juanita Lopez, S. Piha-Paul, 2016 .

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

N. Agarwal, J. Barrett, C. Corcoran, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.

C. Drake, S. Park, E. Antonarakis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.

M. Kibukawa, R. Cristescu, Lixin Lang, 2022, The Journal of molecular diagnostics : JMD.

73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis

J. Carles, J. Bono, S. Oudard, 2021, Annals of Oncology.

Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.

J. Bono, L. Appleman, G. Gravis, 2020 .

Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.

J. Bono, L. Appleman, G. Gravis, 2020 .

Establishment and characterization of an oxaliplatin-resistant hepatic cancer cell line

Gang Chen, H. Qiu, Yuhong Dai, 2018, Oncology and Translational Medicine.

Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.

C. Corcoran, A. Barnicle, E. Harrington, 2021 .

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

R. Greil, S. Park, E. Antonarakis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.